

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI
Charmacy Pharmaceutical Co., Ltd.
創美藥業股份有限公司

(A joint stock limited liability company incorporated in the People's Republic of China)
 (Stock Code: 2289)

**POLL RESULTS OF THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
 HELD ON 27 DECEMBER 2024**

References are made to the announcement dated 8 November 2024, the notice of the 2024 second extraordinary general meeting dated 9 December 2024 (the "**Notice of EGM**") and the circular dated 9 December 2024 (the "**Circular**") of Charmacy Pharmaceutical Co., Ltd. (the "**Company**"). Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

POLL RESULTS OF THE EGM

The Board is pleased to announce that the resolutions proposed as set out in the Notice of EGM were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
1.	THAT the framework agreement dated 8 November 2024 (the " New Framework Sales Agreement ") entered into between the Company and Jiangyao Group Co., Ltd* (江藥集團有限公司) (" Jiangyao ") for the sales of medicines, medical devices, healthcare products and food for which the Company and its subsidiaries (the " Group ") act as a distributor which purchases products directly from pharmaceutical manufacturers or their pharmaceutical distributor companies (regardless of whether it has obtained an exclusive distribution right or not) (the " Primary Distributor ") to Jiangyao and its subsidiaries (the " Jiangyao Group ") and the proposed annual caps for the transactions contemplated thereunder, be and are hereby approved and confirmed.	43,837,000 (100%)	0 (0%)	0 (0%)

2	THAT the framework agreement dated 8 November 2024 (the " New Framework Purchase Agreement ") entered into between the Company and Jiangyao for the purchase of medicines, medical devices, healthcare products and food for which Jiangyao Group acts as a Primary Distributor from Jiangyao Group and the proposed annual caps for the transactions contemplated thereunder, be and are hereby approved and confirmed.	43,837,000 (100%)	0 (0%)	0 (0%)
3	THAT any one director of the Company be and is hereby authorised to sign or execute such other documents or supplemental agreements or deeds on behalf of the Company and to do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the New Framework Sales Arrangement and the New Framework Purchase Agreement and completing the transactions contemplated thereunder with such changes as he/she may consider necessary, desirable or expedient.	43,837,000 (100%)	0 (0%)	0 (0%)

As more than 50% of the votes were cast in favour of the resolutions numbered 1 to 3, these resolutions were duly passed as ordinary resolutions of the Company.

Notes:

1. As at the date of the EGM, the total number of issued Shares was 108,000,000 Shares, which represented the total number of Shares entitling the holders to attend and vote on the proposed resolutions at the EGM. The Company did not hold any treasury share and no voting right of treasury shares has been exercised at the EGM.

2. Except for Jiangyao, parties acting in concert with it and their respective associates (in respect of 51,470,000 Shares) who were required to abstain from voting in relation to the above resolutions, there were no Shares entitling the holders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM pursuant to Rule 13.40 of the Listing Rules, nor were there any Shareholders who were required under the Listing Rules to abstain from voting at the EGM.

3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the proposed resolutions at the EGM.

4. For the above resolutions, the Shareholders, proxies or authorised representatives holding in aggregate of 43,837,000 Shares, representing approximately 77.55% of the total voting Shares, were present in person or by proxy at the EGM.

5. Pursuant to the Listing Rules, SHINEWING Certified Public Accountants (Special General Partnership), the auditors of the Company for the year 2024, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

6. The attendance record of the Directors at the EGM was as follows:

Mr. Yao Chuanglong attended in person; and

Ms. Zheng Yuyan, Ms. Zhang Hanzi, Mr. Yan Jingbin, Ms. Fu Zheng, Mr. Xu Fei, Mr. Li Hanguo, Mr. Wan Chi Wai Anthony and Mr. Guan Jian attended by electronic means.

By order of the Board
Charmacy Pharmaceutical Co., Ltd.
Yan Jingbin
Chairman

Shantou, the PRC, 27 December 2024

As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive Directors are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive Directors are Mr. Li Hanguo, Mr. Wan Chi Wai Anthony and Mr. Guan Jian (also known as Guan Suzhe).